Literature DB >> 7843184

Pharmacokinetics and suction blister fluid penetration of a semisynthetic injectable streptogramin RP 59500 (RP 57669/ RP 54476).

E Bernard1, M Bensoussan, F Bensoussan, S Etienne, I Cazenave, E Carsenti-Etesse, Y Le Roux, G Montay, P Dellamonica.   

Abstract

RP 59500 is a new semisynthetic injectable streptogramin with excellent activity against most gram-positive bacteria. In order to assess its potential for the treatment of tissue infections, the pharmacokinetics and penetration into suction blister fluid were studied in a pilot phase I study in six male volunteers following a single infusion of 12 mg/kg over 1 h. Plasma and suction blister fluid concentrations were determined by microbiological assay. The mean peak concentration in plasma was 8.65 mg/l at the end of infusion. The mean plasma elimination half-life was 1.48 h. The mean peak concentration in interstitial fluid was 2.41 mg/l and was reached after 1 h in two volunteers and after 2 h in the other four. The mean percentage penetration for the interval 0-6 h was 82.5%. RP 59500 was still detectable in interstitial fluid at 6 h at a mean concentration of 0.92 +/- 0.25 mg/l. The data of this pilot study demonstrate good penetration of RP 59500 into non-inflammatory interstitial fluid.

Mesh:

Substances:

Year:  1994        PMID: 7843184     DOI: 10.1007/bf02276064

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  11 in total

1.  A phase I, double-blind, placebo-controlled study of the tolerance and pharmacokinetic behaviour of RP 59500.

Authors:  S D Etienne; G Montay; A Le Liboux; A Frydman; J J Garaud
Journal:  J Antimicrob Chemother       Date:  1992-07       Impact factor: 5.790

2.  The in-vitro activity of RP 59500 against gram-positive cocci.

Authors:  S Goto; S Miyazaki; Y Kaneko
Journal:  J Antimicrob Chemother       Date:  1992-07       Impact factor: 5.790

3.  In-vitro activity of RP 59500, a semisynthetic streptogramin, against staphylococci and streptococci.

Authors:  J C Pechère
Journal:  J Antimicrob Chemother       Date:  1992-07       Impact factor: 5.790

Review 4.  The clinical relevance of protein binding and tissue concentrations in antimicrobial therapy.

Authors:  R Wise
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

Review 5.  Significance of tissue levels for prediction of antibiotic efficacy and determination of dosage.

Authors:  C Carbon
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-07       Impact factor: 3.267

Review 6.  Pharmacokinetics of tissue penetration of antibiotics.

Authors:  T Bergan
Journal:  Rev Infect Dis       Date:  1981 Jan-Feb

7.  Dermo-epidermal separation with suction. Electron microscopic and histochemical study of initial events of blistering on human skin.

Authors:  U Kiistala; K K Mustakallio
Journal:  J Invest Dermatol       Date:  1967-05       Impact factor: 8.551

8.  In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

9.  Cellular uptake and intracellular bactericidal activity of RP 59500 in murine macrophages.

Authors:  J F Desnottes; N Diallo
Journal:  J Antimicrob Chemother       Date:  1992-07       Impact factor: 5.790

10.  Antimicrobial activity against Staphylococcus aureus of semisynthetic injectable streptogramins: RP 59500 and related compounds.

Authors:  J C Barrière; D H Bouanchaud; J M Paris; O Rolin; N V Harris; C Smith
Journal:  J Antimicrob Chemother       Date:  1992-07       Impact factor: 5.790

View more
  3 in total

1.  Biodistribution of etanercept to tissues and sites of inflammation in arthritic rats.

Authors:  Xi Chen; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  Drug Metab Dispos       Date:  2015-04-01       Impact factor: 3.922

Review 2.  Quinupristin-dalfopristin.

Authors:  H M Bryson; C M Spencer
Journal:  Drugs       Date:  1996-09       Impact factor: 9.546

Review 3.  Clinical pharmacokinetics of quinupristin/dalfopristin.

Authors:  David T Bearden
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.